1607-Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) dose dense followed by PACLitaxel dose de | eviQ
Update on systemic treatment for newly diagnosed inflammatory breast cancer - ScienceDirect
Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study - ScienceDirect
Pregnancy-Associated Breast Cancer
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Protocol MCP841 chemotherapy regimen. | Download Table
Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052) | Scientific Reports
Cancers | Free Full-Text | Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
JCM | Free Full-Text | Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)
Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel... | Download Table
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome | Nature Communications
Standardizing Chemotherapy Regimen Nomenclature: A Proposal and Evaluation of the HemOnc and National Cancer Institute Thesaurus Regimen Content | JCO Clinical Cancer Informatics
Chemotherapy protocol a for HR ALL patients | Download Table
Timing of AC chemotherapy cycles for breast cancer patients initiating... | Download Scientific Diagram
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial - The Lancet
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Breast Cancer Update .com - Web Guide 1 2003
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial - The Lancet
SWOG S 0800 ( NCI CDR 0000636131 ) : addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response ( pCR ) rates in inflammatory or locally
Chemotherapy Administration Sequencing: An Update on the Current Literature
Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
Chemotherapy for Uterus Cancer
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial - The Lancet Oncology
Recommended antiemetic regimens for HEC and AC-containing regimens... | Download Table
